Kenneth L. Custer
Eli Lilly (United States)(US)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, Long-Term Effects of COVID-19, SARS-CoV-2 and COVID-19 Research, Cellular transport and secretion, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19(2020)1,420 cited
- → Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19(2021)941 cited
- → Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities(2021)208 cited
- → Synaptic Vesicle Protein 2 Enhances Release Probability at Quiescent Synapses(2006)204 cited
- → SV2 regulates neurotransmitter release via multiple mechanisms(2010)138 cited
- → SV2A and SV2C contain a unique synaptotagmin-binding site(2005)93 cited
- → A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load(2021)68 cited
- → Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial(2021)12 cited
- → A high-throughput method for generating uniform microislands for autaptic neuronal cultures(2011)9 cited